GIP at 20 nM had no major effect on adipogenic gene expression, while 10 nM Tirzepatide reduced insulin receptor (INSR) and ADIPOQ levels
In particular, dedicated outcome trials have shown that SGLT-2Is significantly slow CKD progression and reduce adverse kidney-related outcomes in patients with CKD regardless of diabetes status [5,6,7]
Limited availability of GLP-1 injections due to stock issues
Common APIs in this subcategory include biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose co-transporter 2 (SGLT2) inhibitors
Benzodiazepines, appetite, and taste palatability